Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
暂无分享,去创建一个
C. Nicco | B. Weill | C. Chéreau | F. Batteux | W. Marut | N. Kavian | A. Servettaz
[1] Gang Han,et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma , 2011, International journal of cancer.
[2] T. Skorski,et al. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. , 2011, Cancer research.
[3] Andrew Wang,et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. , 2010, Arthritis and rheumatism.
[4] M. Mayes,et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial , 2010, Annals of the rheumatic diseases.
[5] Sarah A. Pendergrass,et al. Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury , 2010, PloS one.
[6] Jun-ji Ma,et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. , 2010, Journal of hepatology.
[7] M. Humbert,et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. , 2010, Rheumatology.
[8] T. Makino,et al. Serum levels of soluble vascular endothelial growth factor receptor‐2 in patients with systemic sclerosis , 2009, The British journal of dermatology.
[9] Ming-Chih Crouthamel,et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors , 2009, British Journal of Cancer.
[10] Y. Gho,et al. Vascular Endothelial Growth Factor Is a Key Mediator in the Development of T Cell Priming and Its Polarization to Type 1 and Type 17 T Helper Cells in the Airways1 , 2009, The Journal of Immunology.
[11] C. Goulvestre,et al. Selective Oxidation of DNA Topoisomerase 1 Induces Systemic Sclerosis in the Mouse1 , 2009, The Journal of Immunology.
[12] Howard Y. Chang,et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. , 2009, Arthritis and rheumatism.
[13] M. Matucci-Cerinic,et al. Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. , 2008, Rheumatology.
[14] M. Trojanowska. Role of PDGF in fibrotic diseases and systemic sclerosis. , 2008, Rheumatology.
[15] D. Baran,et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. , 2008, Rheumatology.
[16] Oliver Distler,et al. Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] Johanna Andrae,et al. Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.
[18] S. Lepreux,et al. The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study , 2008, Dermatology.
[19] A. Ochsenbein,et al. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. , 2006, Blood.
[20] M. Shibuya,et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. , 2006, Blood.
[21] A. Gabrielli,et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.
[22] A. Freemont,et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. , 2006, Human pathology.
[23] S. Svegliati,et al. Platelet-derived Growth Factor and Reactive Oxygen Species (ROS) Regulate Ras Protein Levels in Primary Human Fibroblasts via ERK1/2 , 2005, Journal of Biological Chemistry.
[24] Jeffrey W. Clark,et al. Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.
[25] K. Csiszȧr,et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis , 2005, Arthritis research & therapy.
[26] A. Kuryliszyn-Moskal,et al. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement , 2005, Clinical Rheumatology.
[27] M. Burdick,et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.
[28] U. Eriksson,et al. The PDGF family: four gene products form five dimeric isoforms. , 2004, Cytokine & growth factor reviews.
[29] Till Acker,et al. Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.
[30] T. Brümmendorf,et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. , 2004, Blood.
[31] C. Denton,et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.
[32] Y. Konttinen,et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin , 2003, Clinical Rheumatology.
[33] M. Conforti,et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.
[34] P. Carmeliet,et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.
[35] A. Mantovani,et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.
[36] C. Strange,et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. , 1995, The Journal of rheumatology.
[37] B. Chua,et al. Myofibroblasts from Scleroderma Skin Synthesize Elevated Levels of Collagen and Tissue Inhibitor of Metalloproteinase (TIMP-1) with Two Forms of TIMP-1 (*) , 1995, The Journal of Biological Chemistry.
[38] C. Heldin,et al. Regulation of fibroblast-mediated collagen gel contraction by platelet-derived growth factor, interleukin-1 alpha and transforming growth factor-beta 1. , 1992, Journal of cell science.
[39] M. Trojanowska,et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts , 1992, The Journal of experimental medicine.
[40] R. Gay,et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. , 1989, The Journal of investigative dermatology.
[41] Oliver Distler,et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. , 2009, Arthritis and rheumatism.
[42] N. Ferrara. The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.
[43] Toshiyuki Yamamoto,et al. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. , 2002, Clinical immunology.